Drug intelligence / Profile preview

BI 11054 CL

Development stage: Phase 1
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Inhalation

Overview

BI 11054 CL is an investigational drug developed by Boehringer Ingelheim. It has been studied in clinical trials as an inhaled therapy, administered via the Respimat device, with a focus on evaluating its safety, tolerability, and pharmacokinetics in healthy male volunteers. The specific mechanism of action and therapeutic indication for BI 11054 CL have not been disclosed in publicly available sources. There is no evidence that it has reached advanced clinical development or approval stages[1].

Other names: BELVIQ-Boehringer Ingelheim-asthma-chronic obstructive pulmonary disease

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on BI 11054 CL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 11054 CL.

Explore the full profile